Study of IMC-P115C in Advanced PRAME-Positive Cancers
Status:
RECRUITING
Trial end date:
2029-08-30
Target enrollment:
Participant gender:
Summary
Phase 1 First-in-human study of the safety and efficacy of IMC-P115C as a single agent and in combination with standard of care (SOC) agents in participants with advanced PRAME positive cancers. IMC-P115C is a half-life extended (HLE) ImmTAC targeting PRAME.